Skip Navigation

Combined therapy can reduce chance of recurrence in women with small, HER2 breast tumors, study shows

    • Eric Winer, MD

      In a phase 2 clinical trial, women with small (stage 1), HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted drug following surgery were highly unlikely to have the cancer recur within three years of treatment, investigators at Dana-Farber Cancer Institute and other institutions report in a paper published today by the New England Journal of Medicine.

      The findings may help establish the therapy – which combines the chemotherapy agent paclitaxel and the targeted drug trastuzumab (Herceptin) – as the first standard treatment approach for this group of patients, the authors state.

      Many previous studies excluded women with small (less than 2 cm in diameter) HER2-positive breast tumors that hadn’t spread to nearby lymph nodes from clinical trials of trastuzumab, because it wasn’t considered prudent to expose them to an investigational drug, given the relatively low risk that the disease would recur. Without a single, standard treatment for this group of patients, treatment approaches have varied widely. (Breast cancers are classified as HER2-positive if their cells have surplus human epidermal growth factor receptors on their surface, making them extra-sensitive to signals to grow and divide.)

      “Women with small, HER-2 positive, node-negative [no sign of spread to adjacent lymph nodes] breast tumors have a low, but still significant, risk of recurrence of their disease,” said the study’s senior author, Eric Winer, MD, director of the Breast Oncology Program at the Susan F. Smith Center for Women’s Cancers at Dana-Farber. “This study demonstrates that a combination of lower-intensity chemotherapy and trastuzumab – which is associated with fewer side effects than traditional chemotherapy regimens – is an appealing standard of care for this group of patients.”

    Posted on January 07, 2015

    • Eric P. Winer, MD
    • Research
    • Breast Cancer
    • Media Contacts

      For all inquiries, call 617-632-4090 and ask to speak to a member of the media team. Please direct emails to

    • New Patient Appointments

      For adults: 877-442-3324
      For children: 888-733-4662

      Make Appointment Online